Navigation Links
TriLink BioTechnologies Launches CleanAmp™ 7-deaza-dGTP for GC-rich Target Amplification
Date:12/16/2010

SAN DIEGO, Dec. 16, 2010 /PRNewswire/ -- TriLink BioTechnologies (TriLink), a leading provider of custom nucleic acid-based products, today announced the launch of an innovative Hot Start solution for the PCR amplification of problematic GC-rich sequences, CleanAmp 7-deaza-dGTP.

When DNA targets high in GC-content are amplified, PCR product formation can often be compromised by inadequate strand separation and the propensity for complex secondary structure formation. The use of standard 7-deaza-dGTP is a notable method for overcoming this problem. TriLink has developed CleanAmp™ 7-deaza-dGTP, an elegant fusion of the secondary structure reducing nucleotide analog 7-deaza-dGTP and TriLink's CleanAmp™ dNTP Hot Start technology. CleanAmp™ 7-deaza-dGTP is available individually for amplification of routine GC-rich targets or as the CleanAmp™ 7-deaza-dGTP Mix which is recommended for more challenging targets with higher GC-content.

"Genetic disease diagnosis commonly involves the detection of GC-rich sequence elements, which have remained a stumbling block in the advancement of personalized medicine. CleanAmp 7-deaza-dGTP is our contribution to advancing this science. We hope it will become an invaluable tool," stated CEO, Richard Hogrefe.

"The amplification of bacteria with high GC-content, such as the pathogenic mycobacterium, is essential for the diagnosis of many deadly diseases such as tuberculosis and leprosy. CleanAmp 7-deaza-dGTP shows promise for the diagnosis of these diseases and the possibility for earlier treatment," stated Scientific Investigator, Natasha Paul.

Visit www.trilinkbiotech.com/cleanamp to learn more.

About TriLink

TriLink BioTechnologies, Inc. manufactures custom oligonucleotides, modified nucleoside triphosphates and CleanAmp™ PCR products for the diagnostic and OEM markets. In addition, custom chemistry, contract research services and ISO/QSR compliant cGMP production facilities are offered.  TriLink's solutions help advance drug discovery and biomedical research.  Founded in 1996, TriLink is a privately held firm based in San Diego, California and employs approximately 75 scientists and other professionals.  For more information about the firm and products, call 858-546-0004, email info@trilinkbiotech.com, or visit our web site at www.trilinkbiotech.com.


'/>"/>
SOURCE TriLink BioTechnologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. TriLink BioTechnologies to Sponsor GIVING HUNGER THE BLUES, a Benefit Concert to Help Alleviate Hunger in San Diego County
2. TriLink BioTechnologies, Inc. Relaunches Oligonucleotide Radiolabeling Services
3. TriLink BioTechnologies, Inc. Launches New Website and OligoBuilder(R)
4. TriLink BioTechnologies to Sponsor Take Me Out to the Ballgame, a SAY San Diego Event Benefiting San Diego Families in Need
5. Epeius Biotechnologies Lead Product, Rexin-G for Metastatic Cancer, Aptly Highlighted by National Cancer Institute Journal
6. Microchip Biotechnologies, Inc. Awarded Contract Under US Army Commercialization Pilot Program
7. Benjamin Custodio Joins Millennium Biotechnologies to Expand International Sales
8. Richter-Helm and Athera Biotechnologies Partner in Development of Recombinant Protein to Treat Cardiovascular Disease
9. Beginners Luck, or Creative Artists of the First Rank? Epeius Biotechnologies Launches Rexin-G eBook Tutorial
10. Commonwealth Biotechnologies Presents Data at Forensic Sciences Meeting Confirming Benefits of ZyGEMs DNA Extraction Technology
11. Solos Endoscopy, Inc. Sells Ovascope and Mastascope Product Line to Lifeline Biotechnologies, Inc.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... ... March 23, 2017 , ... AxioMed president, ... viscous and elastic characteristics when deformed, which is identical to how the human ... absorb compressive forces and return to its natural state along a hysteresis curve, ...
(Date:3/23/2017)... Mass. , March 23, 2017 /PRNewswire/ ... partner to global in vitro diagnostics manufacturers ... of the industry,s first multiplexed Inherited ... disease testing by next-generation sequencing (NGS). The ... were developed with input from industry experts ...
(Date:3/23/2017)... , March 23, 2017 Kineta, ... development of novel therapies in immuno-oncology, today announced ... lead" small molecule compounds that activate interferon response ... pathways and demonstrate immune-mediated tumor regression in a ... the study who demonstrated complete tumor regression to ...
(Date:3/23/2017)... , March 23, 2017 ... at four equities in the Biotech industry: Sangamo Therapeutics ... Biologics Inc. (NYSE MKT: SYN), and Regulus Therapeutics Inc. ... st , 2017, Credit Suisse upgraded its rating on Pharmaceuticals/Biotechnology ... downloading their free report at: ...
Breaking Biology Technology:
(Date:3/22/2017)... Optimove , provider of the ... as 1-800-Flowers and AdoreMe, today announced two new ... Using Optimove,s machine learning algorithms, these features allow ... recommendations to their customers based not just on ... intent drawn from a complex web of data ...
(Date:3/13/2017)... Future of security: Biometric Face Matching software  ... ... DERMALOGs Face Matching enables to match face pictures against each other or against ... (PRNewsFoto/Dermalog Identification Systems) ... Matching" is the fastest software for biometric Face Matching on the market. The ...
(Date:3/6/2017)... March 6, 2017 Mintigo , ... today announced Predictive Sales Coach TM , its ... sales intelligence into Salesforce. This unique AI application ... sales organizations with deep knowledge of their customers ... intelligent engagement. Predictive Sales Coach extends Mintigo,s existing ...
Breaking Biology News(10 mins):